Annual Reports in Medicinal Chemistry

A compendium of information on newly approved drugs and compounds entering late-stage clinical trials, and a valuable resource for graduate students pursuing research in medicinal chemistry

Manoj C Desai (Series edited by)

9780128001677

Paperback, published 29 September 2014

636 pages
22.9 x 15.1 x 3.9 cm, 0.96 kg

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies.

1. A Personal Essay: My Experiences in the Pharmaceutical Industry
2. Adventures in Medicinal Chemistry - A Career in Drug Discovery
3. Natural and Synthetic Neuroactive Steroid (NAS) Modulators of GABA_A and NMDA Receptors
4. Development of LRRK2 Kinase Inhibitors for Parkinson’s Disease
5. Stimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders
6. Small Molecule Modulators of GPR40 (FFA1)
7. Recent Advances in the Development of P2Y₁₂ Receptor Antagonists as Antiplatelet Agents
8. Current Approaches to the Treatment of Atrial Fibrillation
9. Advances in the Discovery of Small Molecule IRAK4 Inhibitors
10. H₄ Receptor Antagonists and Their Potential Therapeutic Applications
11. Urate Crystal Deposition Disease and Gout - New Therapies for an Old Problem
12. p53 - MDM2 and MDMX Antagonists
13. Modulators of Atypical Protein Kinase C as Anticancer Agents
14. Advancement of Cell Wall Inhibitors in Mycobacterium Tuberculosis
15. Nucleosides and Nucleotides for the Treatment of Viral Diseases
16. Advances in Inhibitors of Penicillin Binding Proteins and ß-lactamases as Antibacterial Agents
17. Tumor Microenvironment as Target in Cancer Therapy
18. Novel Screening Paradigms for the Identification of Allosteric Modulators and /or Biased Ligands for Challenging G-Protein-Coupled Receptors (GPCRs)
19. Mer Tyrosine Kinase Receptor: Therapeutic Opportunities in Oncology, Virology and Cardiovascular Indications
20. Disease Modifying Agents for the Treatment of Cystic Fibrosis
21. Advancements in Stapled Peptide Drug Discovery and Development
22. Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development
23. Case History: Forxiga^TM (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes
24. Case History: Kalydeco® (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation
25. Case History: Xeljanz^TM (Tofacitinib Citrate), A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis
26. New Chemical Entities Entering Phase III Trials in 2013
27. To Market, To Market – 2013

Subject Areas: Organic chemistry [PNN], Pharmacology [MMG]